

1 **Supplementary data**

2


qPCR	Forward primer	Reverse primer
<i>Lactobacillus murinus</i>	TCGAACGAAACTTCTTTATCACC	CGTTCGCCACTCAACTCTTT
<i>Lactobacillus johnsonii</i>	TCGAGCGAGCTTGCCTAGATGA	TCCGGACAACGCTTGCCACC
<i>Lactobacillus Universal</i>	GAGGCAGCAGTAGGGAATCTTC	CCAGCGTTGCCACCTACGTA
<i>Eubacteria 16S</i>	CGGCAA CGAGCGCAACCC	CCATTGTAGCACGTGTGTAG CC
Tumor necrosis factor alpha	CTGAACTTCGGGGTGATCGG	GGCTTGTCACTCGAATTTTGAGA
Interferon gamma	GCCACGGCACAGTCATTGA	TGCTGATGGCCTGATTGTCTT

3 **Supplementary Table 1.** Primers for bacteria and cytokines.

4

5 **Supplementary Figure.**


6



7


8 **Supplementary Figure 1.** Early, late, and total cell apoptosis of CRC tumor cells using Annexin V-  
9 FITC/PI staining. Control: n=5; FMD: n=5.

10




11

12 **Supplementary Figure 2.** Flow cytometry gating strategy of CD45<sup>+</sup> cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells,  
13 NK cells, DC cells and macrophage.



14  
 15 **Supplementary Figure 3.** FMD changed gut microbiota composition. **a.** Significant species alterations  
 16 in control and FMD groups on family level. **b.** Plot summarizing the percentage community of abundance  
 17 of microbial families in fecal samples from the control and FMD groups. **c.** LefSe used to identify the  
 18 differentially expressed bacterial taxa in two groups (family to genus level); the size and color of circles  
 19 indicate the abundance of the bacterial. **d.** qPCR verification of fecal abundance of *L. johnsonii* and *L.*  
 20 *murinus*. **e.** PICRUSt2 prediction of KEGG enzyme abundance from 16S rRNA, showing the top 10  
 21 most abundant enzymes. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .  
 22



23

24 **Supplementary Figure 4.** The role of *Lactobacillus* and *L. johnsonii* in modulating tumor growth during  
 25 FMD. **a.** Schematic diagram of FMD and vancomycin regimen. **b.** qPCR verification of fold change of  
 26 *Lactobacillus* and *L. johnsonii* after vancomycin treatment before FMD started. **c.** MC38 cells were  
 27 injected subcutaneously into C57BL/6 mice. Image of dissected tumors at day 24. Upper: FMD group;  
 28 lower: FMD + vancomycin group. **d.** Tumor weight on day of sacrifice. **e.** Average tumor volume  
 29 measured after MC38 cells injection. FMD group: n=7; FMD+V: n=7. Student t test. Data are shown in  
 30 mean  $\pm$  SD. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.